For decades, a mesothelioma diagnosis has felt like a near-certain death sentence for patients and their families. This aggressive cancer, typically caused by asbestos exposure, leaves an affected person with few treatment options and even lesser long-term survival prospects.
However, a groundbreaking clinical trial gives a ray of optimism by showing that a novel treatment can significantly extend patients’ lives.
Mesothelioma and Its Persistent Threats
Mesothelioma is a rare type of cancer that grows in the thin layer of tissue covering specific internal organs. One common type is pleural mesothelioma, which predominantly affects the lining of the lungs. Such a disease usually develops decades after exposure to asbestos, a natural mineral once prized for its durability and resistance to various chemicals but is now treated as an occupational hazard.
Due to its long latency period, which may take up to 50 years, many patients do not receive diagnoses until the disease is already in an advanced stage where treatment options are limited.
Although mesothelioma can affect anyone, veterans are particularly vulnerable due to their frequent exposure to asbestos during their service. Several military settings, especially in the 20th century, used this harmful mineral in shipbuilding, vehicle maintenance, and construction.
This placed service members at a higher risk of developing aggressive cancer. About 30% of the 3,000 Americans diagnosed with mesothelioma each year are veterans, highlighting the disproportionate impact this disease has on those who served in the military.
How Mesothelioma Affects California
California is known to have a long history of asbestos exposure, especially with the mineral deposits found in 42 of its 58 counties. This natural presence, combined with widespread industrial use, has resulted in high rates of asbestos-associated diseases, including mesothelioma. Between 1999 and 2017, the Golden State reported 27,080 asbestos-related fatalities, with 5,100 of those cases linked to mesothelioma.
San Diego is among the many counties in California drastically impacted by asbestos exposure. It has recorded the second-highest number of asbestos-related deaths, totaling 2,905. The stakes are even higher for veterans residing here, which stands at over 200.000 — the largest veteran population in the country and one of the world’s largest concentrations of military personnel. Many served at military bases with asbestos-containing materials, significantly increasing their exposure risk.
The San Diego Air Pollution Control District now regulates renovation and demolition projects to ensure proper asbestos removal from affected buildings. But despite this effort, the damage from the past extensive contamination has already continued to impact many, specifically veterans who were unknowingly exposed during their service.
New Clinical Trial Brings Hope to Mesothelioma Patients
A recent clinical trial, the ATOMIC-Meso Trial, offers new possibilities for mesothelioma patients. This study tested the effectiveness of pegargiminase (ADI-PEG20) in treating cancer when combined with standard chemotherapy. Pegargiminase is an anti-cancer agent that deprives tumors of arginine, an amino acid necessary for their growth. By starving the tumors of arginine, pegargiminase helps to stop cancer cells from thriving, leading to their eventual death.
The results are so far encouraging. Adding pegargiminase to chemotherapy reduced the death risk by 29%, extending the median overall survival from 7.7 months to 9.3 months. The novel treatment also presented longer progression-free survival, with a median of 6.2 months compared to 5.6 months for patients receiving placebo chemotherapy. What’s more promising is that such medication was well-tolerated by the study participants and did not introduce new safety concerns.
This breakthrough is a promising step forward in the fight against mesothelioma. It brings new hope for patients, showing that more effective medications are on the horizon. For doctors and other healthcare providers, it signals an exciting shift in treatment options while underscoring the urgent need to make innovative therapies like this more accessible to those who need them most.
This is a crucial milestone in mesothelioma care, giving patients and families something to look forward to.
Jonathan Sharp is a chief financial officer of the Environmental Litigation Group, P.C., in Birmingham, Alabama. The firm extends legal support to victims of toxic environmental exposure and their families.
